课题基金 / 基金详情

Ocular Growth, Emmetropia, and Interphotoreceptor Retinoid-Binding Protein (IRBP)

Ocular Growth, Emmetropia, and Interphotoreceptor Retinoid-Binding Protein (IRBP)
眼睛生长、正视眼和感光器间视黄醇结合蛋白 (IRBP)
批准号:
9769038
负责人:
JEFFREY H BOATRIGHT
金额:
$43.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2022-06-30

项目摘要

项目成果

JEFFREY H BOATRIGHT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SUMMARY IRBP is expressed much earlier than needed for any putative role in the visual cycle. In the previous grant cycle, we showed that IRBP is needed in early retina development, as without it we detected morphological changes coincident with terminal differentiation of rods and cones, and precocious development of the outer plexiform layer. At the same time, we discovered excessive eye growth and elongation of the optical axis starting distinctly at P7. This implies a role for IRBP in controlling eye growth even without vision-based signaling. We now know that IRBP loss causes diverse and severe eye diseases including profound myopia and retinal degeneration, and we recently discovered sluggish pupillary light reflexes (PLRs). In recent human GWAS studies, IRBP polymorphisms are associated with refractive error and corneal curvature. Previous linkage studies established that IRBP defects caused combined RP and severe myopia. We view abnormalities of IRBP deficiency in the context of eye disease that affect normal determination of eye size, based on strong and abundant previous and concurrent work in developmental biology of the Drosophila eye and organ size fate. We test the same five principal pathways that regulate size determination in the IRBP knockout eye. We seek to understand posited hierarchical relationships among myopia, RD, and other abnormalities in IRBP mutations. To do that we have constructed and validated a new conditional knockout (KO) mouse and a new traditional KO. Here we use them to sort out the temporal, spatial, and mechanistic relationships that cause these three major symptoms. Last, we test efficacy of drugs known to slow myopia or organ size, in the IRBP-/- model asking if they are effective in reducing any or all IRBP deficiency symptoms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Atypical opsins and the OIR model of retinopathy of prematurity
  • 批准号:
    10675898
  • 项目类别:
  • 资助金额:
    $23.48万
  • 财政年份:
    2023
  • 负责人:
    JEFFREY H BOATRIGHT
  • 依托单位:
A TrkB Activator for Treatment of Glaucoma
  • 批准号:
    10261458
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    JEFFREY H BOATRIGHT
  • 依托单位:
A TrkB Activator for Treatment of Glaucoma
  • 批准号:
    10475096
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    JEFFREY H BOATRIGHT
  • 依托单位:
The RPE and Recovery of the Blood Retina Barrier
  • 批准号:
    10163852
  • 项目类别:
  • 资助金额:
    $47.14万
  • 财政年份:
    2018
  • 负责人:
    JEFFREY H BOATRIGHT
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: